Gout
📧 Sign up to get email alerts when something new happens for Gout.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-04-12Clinical Trial Update: A Study to Assess the Efficacy, Safety, and Pharmacokinetics of ABP-671 in Patients With Gout or Hyperuricemia [Phase 2]
Phase 2 trial evaluating ABP-671 for efficacy, safety, and pharmacokinetics in gout and hyperuricemia has completed.
-
FDA approval · 2023-03-15FDA Approved: ALLOPURINOL — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
The FDA approved a supplemental application for Allopurinol from Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. under ANDA204…
-
FDA approval · 2023-01-12FDA Approved: ALLOPURINOL — Supplemental Application (Unichem Pharmaceuticals (USA), Inc.)
FDA approved a supplemental application for Allopurinol from Unichem Pharmaceuticals (USA), Inc., indicating approval of a supplement to the…
-
FDA approval · 2023-01-09FDA Approved: FEBUXOSTAT — Original Application (Zydus Lifesciences Limited)
FDA approved Zydus Lifesciences Limited's febuxostat Original Application, granting approval for a generic febuxostat product. Febuxostat is…
-
CLINICAL_TRIALS trial_result · 2023-01-04Clinical Trial Update: An Innovative Chinese Herbal Formula for the Treatment of Gout [Phase 2]
Phase 2 clinical trial update for an innovative Chinese herbal formula targeting gout.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2022-10-28FDA Approved: NAPROXEN SODIUM — Original Application (Camber Consumer Care Inc)
FDA approved Naproxen Sodium generic from Camber Consumer Care Inc under an Original Application (ANDA211065).
-
CLINICAL_TRIALS trial_result · 2022-10-20Clinical Trial Update: A Phase Ib/II Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout [Phase 1, Phase 2]
A Phase Ib/II clinical trial evaluating a recombinant anti-IL-1β monoclonal antibody in Chinese participants with acute gout is in early-pha…
-
FDA approval · 2022-10-06FDA Approved: NAPROXEN AND ESOMEPRAZOLE MAGNESIUM — Original Application (Ajanta Pharma USA Inc.)
FDA approved Ajanta Pharma USA Inc.'s Naproxen and Esomeprazole Magnesium as an Original Application (ANDA213699), providing a generic versi…
-
FDA approval · 2022-09-06FDA Approved: NAPROXEN SODIUM — Supplemental Application (CVS)
The FDA approved a supplemental application for naproxen sodium sponsored by CVS.
-
CLINICAL_TRIALS trial_result · 2022-08-24Clinical Trial Update: Clinical Study of SHR4640 Tablets Combined With Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia [Phase 2]
Phase 2 clinical trial evaluating SHR4640 tablets in combination with febuxostat for primary gout and hyperuricemia.
-
CLINICAL_TRIALS trial_result · 2022-08-24Clinical Trial Update: The Impact of Urate-lowering Therapy on Kidney Function (IMPULsKF) [Phase 4]
A phase 4 clinical trial assessing the impact of urate-lowering therapy on kidney function in patients with gout and chronic kidney disease …
-
FDA approval · 2022-08-08FDA Approved: ALLOPURINOL — Supplemental Application (Gland Pharma Limited)
FDA approved a supplemental application from Gland Pharma Limited for Allopurinol, enabling the marketing of a generic Allopurinol product u…
-
FDA approval · 2022-08-04FDA Approved: ALLOPURINOL — Supplemental Application (Rising Pharma Holdings, Inc.)
The FDA approved a supplemental application for allopurinol submitted by Rising Pharma Holdings, Inc. This action authorizes a post-approval…
-
CLINICAL_TRIALS trial_result · 2022-08-01Clinical Trial Update: Pharmacogenetics of SGLT2 Inhibitors [Phase 4]
Phase 4 trial update on pharmacogenetics of SGLT2 inhibitors; terminated with posted results.
-
CLINICAL_TRIALS trial_result · 2022-07-26Clinical Trial Update: Study of Pegloticase in Participants With Uncontrolled Gout Who Have Had a Kidney Transplant [Phase 4]
This Phase 4 trial evaluated pegloticase in adults with uncontrolled gout who have had a kidney transplant; results were posted in July 2022…
-
CLINICAL_TRIALS trial_result · 2022-07-25Clinical Trial Update: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Evaluation of RPH-104 Administered at Different Doses to Patients With Acute Gout Attack [Phase 2]
Phase 2 clinical trial evaluating safety, tolerability, pharmacokinetics and pharmacodynamics of RPH-104 at different doses in patients with…
-
FDA approval · 2022-07-07FDA Approved: KRYSTEXXA — Supplemental Application (Horizon Therapeutics USA, Inc.)
The FDA approved a supplemental application for KRYSTEXXA (pegloticase) by Horizon Therapeutics USA, Inc., expanding the regulatory authoriz…
-
CLINICAL_TRIALS trial_result · 2022-06-13Clinical Trial Update: A Study of Evaluating the Efficacy and Safety of SHR4640 in Subjects With Gout [Phase 3]
Phase 3 trial evaluating the efficacy and safety of SHR4640 in subjects with gout has completed.
-
FDA approval · 2022-06-07FDA Approved: NAPROXEN — Original Application (Camber Pharmaceuticals, Inc.)
FDA approves Camber's naproxen generic original application for Naproxen. This generic NSAID is approved for relief of pain and inflammation…
-
CLINICAL_TRIALS trial_result · 2022-05-16Clinical Trial Update: Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout [Phase 4]
Phase 4 trial evaluating KRYSTEXXA (pegloticase) plus methotrexate in uncontrolled gout has been completed with results posted.
-
CLINICAL_TRIALS trial_result · 2022-05-13Clinical Trial Update: Topical Application to Relieve Gout: Efficacy Trial & Safety (TARGETS) [Phase 2]
Phase 2 trial update evaluating topical treatment for gout, reporting efficacy and safety outcomes.
-
CLINICAL_TRIALS trial_result · 2022-05-06Clinical Trial Update: D-0120 Safety and PK/PD Study in China [Phase 1, Phase 2]
Phase 1/2 safety and PK/PD trial of D-0120 completed in China for hyperuricemia or gout.
-
CLINICAL_TRIALS trial_result · 2022-04-06Clinical Trial Update: Anakinra vs. Steroids for the Treatment of Gout Attacks in Patients With Renal Disease (ASGARD): A Feasibility Study [Phase 2, Phase 3]
A feasibility study comparing anakinra versus steroids for treating gout attacks in patients with renal disease (ASGARD) completed.
-
FDA approval · 2022-03-28FDA Approved: FEBUXOSTAT — Original Application (Solco Healthcare US LLC)
FDA approved an original abbreviated new drug application for febuxostat submitted by Solco Healthcare US LLC.
-
FDA approval · 2022-03-11FDA Approved: NAPROXEN — Supplemental Application (Granules India Ltd)
FDA approved a supplemental application for naproxen sodium granules from Granules India Ltd, resulting in an approved supplemental request …